Roche has seen the impact from biosimilar competition ease in recent periods, with management noting that the drag from biosimilars on legacy cancer drugs like Avastin, Herceptin, and Rituxan is slowing down and becoming less severe on the overall portfolio.
At the same time, sales of the key eye drug Vabysmo have recently slumped, especially in the U.S., where revenue missed expectations and fell year‑on‑year in the second quarter of 2026 due to weaker demand, end of certain patient‑support programs, and market stabilization after earlier rapid growth.
Despite the Vabysmo disappointment, Roche is confirming its 2026 outlook, citing strong performance from other growth drivers such as Xolair, Hemlibra, Ocrevus, and Phesgo, which continue to offset declines from older, biosimilar‑exposed products.
Sources:
Roche's Second-Quarter Sales Held Back by Blockbuster Eye Drug
Roche confirms outlook despite Vabysmo miss, currency headwinds
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
Roche's COVID drugs tumble $1B as new eye launch ...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales ...
UPDATE 1-Eye drug success mitigates Roche's earnings decline
Roche Q1 sales decline tempered by swift uptake of new eye drug
Roche shares fall as new drug sales disappoint
Roche Shares Drop 2.8% as Vabysmo and Hemlibra Sales ...
How This Multibillion-Dollar Company Is Shaking Off the Competition | The Motley Fool
Roche defends 6B franc Vabysmo peak target despite ...
Vabysmo gains ground, biosimilars struggle to take off - BioCentury